Study on BMS-986490 With or Without Bevacizumab for Advanced Solid Tumors

Inclusion Criteria

• Have a confirmed diagnosis of an advanced solid tumor that cannot be surgically removed or has spread to other parts of the body, and can be measured by standard criteria.
• For colorectal cancer (CRC):
  • Have advanced or metastatic colorectal cancer with adenocarcinoma that has worsened after receiving standard cancer treatments, including 5-FU, irinotecan, and/or oxaliplatin, if available and appropriate.
• For non-small cell lung cancer (NSCLC):
  • Have NSCLC that is at an advanced stage (Stage IIIB, Stage IV, or recurrent) and has worsened after at least two previous treatments.
  • Must have received and progressed after anti-PD-(L)1 therapy, if available.
• For gastric cancer (GC):
  • Have received and either not responded to or could not tolerate at least one standard treatment for advanced or metastatic gastric cancer, or the cancer worsened within six months of adjuvant therapy.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

• Have a history of severe allergic reactions to irinotecan and/or bevacizumab.
• Have previously received treatment targeting the CEACAM5 protein.
• Have severe lung conditions like interstitial lung disease (ILD) or pneumonitis of Grade 3 or higher.
• Other specific criteria as defined in the study protocol.